AbbVie (ABBV) Tops Quarterly Estimates with $15 Billion Revenue

AI Summary

AbbVie (ABBV) reported quarterly revenue of $15 billion, exceeding analyst expectations of $14.72 billion. Profit per share was $2.65, surpassing forecasts of $2.59. Skyrizi sales reached $4.48 billion, growing 30.9%, while Rinvoq saw a 23.3% increase to $2.12 billion. In contrast, Humira's sales decreased by 38.6% to $688 million, missing estimates of $696.5 million. AbbVie also raised its adjusted earnings forecast for the year to $14.08 to $14.28 per share from the previous range of $13.96 to $14.16.